Speed To Clinic

Does or should speed to clinic impact a company’s decision to build versus buy? When it comes to capacity and anticipated demand, what were some of the things Kite accomplished with its facility that are now considered best practices? What about lessons learned regarding capacity and meeting anticipated demand? Panelists Will Junker, Head of Vector Manufacturing Quality at Kite Pharma and Mitch Lower, SVP of Technical Operations at Kriya Therapeutics Junker tackle these questions and more during this segment of Cell & Gene Live “Building An In-House Cell & Gene Manufacturing Facility – Best Practices & Lessons Learned.”